Orrick advised Catalyst Biosciences, Inc. on the deal. South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. announced its acquisition of the F351 program, a next-generation fibrosis drug,...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here